Skip to main content
. 2021 May 31;8:507–512. doi: 10.2147/JHC.S311496

Table 1.

Characteristics of Patients

Value Long-Term Survival Patients Short-Term Survival Patients
No. of patients 5 31
Age at treatment, years Mean 63 61.8
Std error 2.2 1.9
Minimum 57 35
Median 64 63
Maximum 69 81
p-value 0.94
Sex Female, n (%) 0 11 (35.5%)
Male, n (%) 5 (100%) 20 (64.5%)
p-value 0.29
Sorafenib duration of treatment in months Mean 6.2 4.2
Std error 2.4 0.8
Minimum 2 0
Median 6 4
Maximum 15 18
p-value 0.41
AFP Category 1, n (%) 2 (40%) 8 (28.6%)
Category 2, n (%) 1 (20%) 9 (32.1%)
Category 3, n (%) 2 (40%) 11(39.3%)
p-value 1.00
Response to treatment CR or PR 2 (40%) 2 (6.5%)
SD or PD 3 (60%) 29 (93.5%)
p-value 0.084
Tumor burden High 4 (80%) 22 (75.9%)
Low 1 (20%) 7 (24.1%)
p-value 1.00
IrAE grade 3–4 Yes 2 (40%) 0 (0%)
No 3 (60%) 31 (100%)
p-value 0.016
ECOG 0 2 10
1 3 21
Liver cirrhosis Yes 4 24
No 1 7
Cause of liver disease Hepatitis B 1 9
Hepatitis C 3 22
Other 1
Child–Pugh score 5 2 17
6 2 10
7 4
NA 1
BCLC B 3 13
C 2 18

Abbreviations: No., number; Std error, standard error; AFP, alpha fetoprotein; IrAE, immune-related adverse event; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer.